TRATAMIENTO CON ERITROPOYETINA HUMANA RECOMBINANTE

TRATAMIENTO CON ERITROPOYETINA RECOMBINANTE 67
112. Kayemba-Kays’s S, Christin P, Yahouanc-Lapalle H, Oriot
D. Anémie néonatale par incompatibilité rhésus traitée par
érythropoiétine. Arch Pediatr 2004; 11: 868-9.
113. Knight K, Wade S, Balducci L. Prevalence and outcomes
of anemia in cancer: A systematic review of the literature.
Am J Med 2004; 116: 11S-26S.
114. Michon J. Incidence of anemia in pediatric cancer
patients in Europe: results of a large, international survey.
Med Pediatr Oncol 2002; 39: 448-50.
114b. Ludwig H, Barrett-Lee PJ, Gascon P, Scneider M, Van
Belle S. European Cancer Anemia Survey (ECAS) defines
factors surrounding anemia in thousands cancer
patients. Proc Am Soc Clin Oncol 2002; 21: 387(a)
115. Ferrario E, Ferrari L, Bidoli P, et al. Treatment of cancerrelated
anemia with epoetin alfa: a review. Cancer Treat
Rev 2004; 30: 563-75.
116. Bokemeyer C, Oechsle K, Hartmann JT. Treatmentinduced
anaemia and its potential clinical impact in
patients receiving sequential high dose chemotherapy for
metastatic testicular cancer. Br J Cancer 2002; 87: 1066-
71.
117. Caro JJ, Salas M, Ward A. Anemia as an independent
prognostic factor for survival in patients with cancer: A
systematic, quantitative review. Cancer 2001; 91: 2214-
21.
118. Aapro M, San Miguel J. Evolving treatment strategies for
anaemia in cancer: experience with epoetin beta.
Oncology 2004; 67 (Suppl 1): 17-22.
119. Witzig TE, Silberstein PT, Loprinzi CL, et al. Phase III,
randomized, double-blind study of epoetin alfa versus
placebo in anemic patients with cancer undergoing
chemotherapy. J Clin Oncol 2004; Sept 27: (Epub).
120. Demetri GD, Kris M, Wade J, Degos L, Cella D, for the
Procrit Study Group. Quality-of-life benefit in chemotherapy
patients treated with epoetin alfa is independent
of disease response or tumor type: results from a
prospective community oncology study. J Clin Oncol 1998;
16: 3412-25.
121. Gabrilove JL, Cleeland CS, Livingston RB, Sarokhan B,
Winer E, Einhorn LH. Clinical evaluation of once-weekly
dosing of epoetin alfa in chemotherapy patients: improvements
in hemoglobin and quality of life are similar
to three-times-weekly dosing. J Clin Oncol 2001; 19:
2875-82.
122. Littlewood TJ, Bajetta E, Nortier JW, Vercammen E,
Rapoport B, for the Epoetin Alfa Study Group. Effects of
epoetin alfa on hematologic parameters and quality of
life in cancer patients receiving nonplatinum chemotherapy:
results of a randomized, double-blind, placebocontrolled
trial. J Clin Oncol 2001; 19: 2865-74.
123. Glaspy J, Bukowski R, Steinberg D, et al. Impact of therapy
with epoetin alfa on clinical outcomes in patients with nonmyeloid
malignancies during cancer chemotherapy in community
oncology practice. J Clin Oncol 1997; 15: 1218-34.
124. Shasha D, George MJ, Harrison LB. Once-weekly dosing
of epoetin-alpha increases hemoglobin and improves
quality of life in anemic cancer patients receiving radiation
therapy either concomitantly or sequentially with
chemotherapy. Cancer 2003; 98: 1072-9.
125. Quirt I, Robeson C, Lau CY. Epoetin alfa in patients not
on chemotherapy - Canadian data. Semin Oncol 2002
29: 75-80.
126. Quirt I, Robeson C, Lau CY. Epoetin alfa therapy
increases hemoglobin levels and improves quality of life
in patients with cancer-related anemia who are not
receiving chemotherapy and patients with anemia who are
receiving chemotherapy J Clin Oncol 2001;19: 4126-34.
127. National Comprehensive Cancer Network: Clinical
Practice Guidelines in Oncology, v.2.2004. Cancer and
treatment-related anemia. Disponible en: http://
www.enccn.com/professionals/physician_gls/PDF/
anemia.pdf
128. Rizzo JD, Lichtin AE, Woolf SH, et al. Use of epoetin in
patients with cancer: evidence-based clinical practice
guidelines of the American Society of Clinical Oncology
and the American Society of Hematology. J Clin Oncol
2002; 20: 4083-107.
129. Bokemeyer C, Aapro MS, Courdi A, et al. EORTC
guidelines for the use of erythropoietic proteins in
anaemic patients with cancer. Eur J Cancer 2004; 40:
2201-16.
129b. Rosberg J, Lefebvre P, Fastenau J. Clinical significance
of a ≥1 gram/deciliter (g/dL) rise in hemoglobin (Hb) at
week 4 (early response) or at week 8 during epoetin alfa
(EPO) treatment. Blood 2003; 102 (abstract 2777).
130. Henry DH, Abels RI. Recombinant human erythropoietin
in the treatment of cancer and chemotherapy-induced
anemia: Results of double-blind and open-label followup
studies. Semin Oncol 1994; 21: 21-8.
131. Cella D, Zagari MJ, Vandoros C et al. Epoetin alfa
treatment results in clinically significant improvements in
quality of life in anemic cancer patients when referenced
to the general population. J Clin Oncol 2003; 21: 366-73.
132. Cazzola M, Messinger D, Battistel V, et al. Recombinant
human erythropoietin in the anemia associated with
multiple myeloma or non-Hodgkin’s Lymphoma: dose
finding and identification of predictors of response. Blood
1995; 86: 4446-53.
133. Cazzola M, Beguin Y, Kloczko J, Spicka I, Coiffier B.
Once-weekly epoetin beta is highly effective in treating
anaemic patients with lymphoproliferative malignancy and
defective endogenous erythropoietin production. Br J
Haematol 2003; 122: 386-93.
134. Lastiri J M, Specterman S, Rendo P, Pallotta MG, Varela
M, Goldztein S. Variables predictivas de respuesta a la
eritropoyetina recombinante humana en pacientes con anemia
y cáncer. Medicina (Buenos Aires) 2002; 62: 41-7.
135. Beguin Y. Prediction of response and other improvements
on the limitations of recombinant human erythropoietin
therapy in anemic cáncer patients. Haematologica 2002;
87: 1209-21.
136. Littlewood TJ, Zagari M, Pallister C, Perkins A. Baseline
and early treatment factors are not clinically useful for
predicting individual response to erythropoietin in anemic
cancer patients. Oncologist 2003; 8: 99-107.
137. Feusner J, Hastings C. Recombinant human erythropoietin
in pediatric oncology: a review. Med Pediatr Oncol
2002; 39: 463-8.
138. Parsons SK. Oncology practice patterns in the use of
hematopoietic growth factors. Curr Opin Pediatr 2000;
12: 10-7.
139. Yilmaz D, Cetimgul N, Kantar M, Oniz H, Kansoy S,
Kavakli K. A single institutional experience: is epoetin
alpha effective in anemic children with cancer? Pediatr
Hematol Oncol 2004; 21: 1-8.
140. Zoubek A, Kronberger M. Early epoetin alfa treatment in
children with solid tumours. Med Pediatr Oncol 2002;
39: 459-62.
141. Buyukpamukcu M, Varan A, Kutluk T, Akyuz C. Is epoetin
alfa a treatment option for chemotherapy-related anemia
in children? Med Pediatr Oncol 2002; 39: 455-8.
142. Kronberger M, Fischmeister G, Poertschger U, Gadner
H, Zoubek A. Reduction in transfusion requirements with
early epoetin alfa treatment in pediatric patients with solid
tumors: a case-control study. Pediatr Hematol Oncol
2002; 19: 95-105.
143. Wagner LM, Billups CA, Furman WL, Rao NB, Santana
VM. Combined use of erythropoietin and granulocyte